Cirilo, PDRREFERÊNCIAS217Jacobson EM, Hugo ER, Borcherding DC et al. Prolactin in breast and prostate cancer: molecular andgenetic perspectives. Discov Med, 11, 315-324, 2011.Jacoby VL, Fujimoto VY, Giudice LC et al. Racial and ethnic disparities in benign gynecologicconditions and associated surgeries. Am J Obstet Gynecol, 202, 514-521, 2010.Jashnani KD, Agrawal VR, Naik LP. Metastasis of breast lobular carcinoma in a cervical leiomyoma.Indian J Pathol Microbiol, 50, 378-379, 2007.Jensen KB, Dredge BK, Stefani G et al. Nova-1 regulates neuron-specific alternative splicing and isessential for neuronal viability. Neuron, 25, 359–371, 2000.Jeong YJ, Noh EM, Lee YR et al. 17beta-estradiol induces up-regulation of PTEN and PPARgamma inleiomyoma cells, but not in normal cells. Int J Oncol, 36, 921-927, 2010.Jiang Y, Suo G and Sadarangani A. Expression profiling of protein tyrosine kinases and their ligandactivators in leiomyoma uteri. Syst Biol Reprod Med, 56, 318–326, 2010.Jin M, Tanaka S, Sekino Y et al. A novel, brain-specific mouse drebrin: cDNA cloning, chromosomalmapping, genomic structure, expression, and functional characterization. Genomics, 79, 686-692, 2002.Jones MR, Italiano L, Wilson SG et al. Polymorphism in HSD17B6 is associated with key features ofpolycystic ovary syndrome. Fertil Steril, 86, 1438-1446, 2006.Jönsson G, Staaf J, Vallon-Christersson J et al. Genomic subtypes of breast cancer i<strong>de</strong>ntified by arraycomparativegenomic hybridization display distinct molecular and clinical characteristics.Breast Cancer Res, 12, 2010.Kallioniemi A, Kallioniemi OP, Sudar D et al. Comparative genomic hybridization for molecularcytogenetics analysis of solid tumors. Science, 258, 818-821, 1992.Kanamori T, Takakura K, Mandai M et al. PEP-19 overexpression in human uterine leiomyoma. MolHum Reprod, 9, 709-717, 2003.Kandalaft PL and Esteban JM. Bilateral massive ovarian leiomyomata in a young woman: a casereport with review of the literature. Mod Pathol, 5, 586-589, 1992.Katoh M. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics andtherapeutics. Expert Rev Anticancer Ther, 10, 1375-1379, 2010.Käufl SD, Makovitzky J, Kuhn C et al. Inhibin/activin-betaC subunit in human endometriala<strong>de</strong>nocarcinomas and HEC-1a a<strong>de</strong>nocarcinoma cell line. In Vivo, 24, 695-698, 2010.Kawaguchi K, Fujii S, Konishi I et al Ultrastructural study of cultured smooth muscle cells fromuterine leiomyoma and myometrium un<strong>de</strong>r the influence of sex steroids. Gynecol Oncol, 21,32-41, 1985.Kayisli UA, Berkkanoglu M, Kizilay G et al. Expression of proliferative and preapoptotic molecules inhuman myometrium and leiomyoma throughout the menstrual cycle. Reprod Sci, 14, 678-686, 2007.
Cirilo, PDRREFERÊNCIAS218Kazmierczak B, Bol S, Wanschura S et al. Pac clone containing the HMGI(Y) gene spans thebreakpoint of a 6p21 translocation in a uterine leiomyoma cell line. Genes ChromosomesCancer, 17, 191-193, 1996.Kazmierczak B, Wanschura S, Rosigkeit J et al. Molecular characterization of 12q14–15rearrangements in three pulmonary chondroid hamartomas. Cancer Res, 55, 2497–2499,1995.Ke L, Che YN, Cao YX et al. Polymorphisms of the HSD17B6 and HSD17B5 genes in Chinese womenwith polycystic ovary syndrome. J Womens Health, 19, 2227-2232, 2010.Khorram O, Garthwaite M, Golos T. Uterine and ovarian aryl hydrocarbon receptor (AHR) and arylhydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign andmalignant gynaecological conditions. Mol Hum Reprod, 8, 75-80, 2002.Kimmich T, Brüning A, Käufl SD et al. Inhibin/activin-betaC and -betaE subunits in the Ishikawahuman endometrial a<strong>de</strong>nocarcinoma cell line. Arch Gynecol Obstet, 282, 185-191, 2010.Kondo NI, Yoshida S, Kajiyama H et al. Metastasis of breast cancer to a uterine leiomyoma. BreastCancer, 16, 157-161, 2009.Kools PF and Van <strong>de</strong> Ven WJ. Amplification of a rearranged form of the high mobility group proteingene hmgic in osteosarcoma cells. Cancer Genet Cytogenet, 91, 1–7, 1996.Kroeger H, Jelinek J, Estécio MR. Aberrant CpG island methylation in acute myeloid leukemia isaccentuated at relapse. Blood, 112, 1366-1373, 2008.Kuivaniemi H, Tromp G, Prockop DJ. Mutations in collagen genes: causes of rare and some commondiseases in humans. FASEB J, 5, 2052-2060, 1991.Laganà A, Russo F, Sismeiro C et al. Variability in the inci<strong>de</strong>nce of miRNAs and genes in fragile sitesand the role of repeats and CpG islands in the distribution of genetic material. PLoS One, 17,e11166, 2010.Lara PC, Lloret M, Clavo B et al. Severe hypoxia induces chemo-resistance in clinical cervical tumorsthrough MVP over-expression. Radiat Oncol, 6, 1-14, 2009.Laser L, Lee P and Wei J. Cellular senescence in usual type uterine leiomyoma. Fertil Steril, 93,2020-2026, 2010.Laurila E, Savinainen K, Kuuselo R et al. Characterization of the 7q21-q22 amplicon i<strong>de</strong>ntifiesARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion inpancreatic cancer. Genes Chromosomes Cancer, 48, 330-339, 2009.Lavecchia A, Di Giovanni C, Novellino E. Inhibitors of Cdc25 phosphatases as anticancer agents: apatent review. Expert Opin Ther Pat, 20, 405-425, 2010.Lea IA, Jackson MA, Li X et al. Genetic pathways and mutation profiles of human cancers: site- an<strong>de</strong>xposure-specific patterns. Carcinogenesis, 28, 1851-1858, 2007.
- Page 1 and 2:
Universidade Estadual Paulista “J
- Page 3:
AGRADECIMENTOSÀ minha orientadora
- Page 10 and 11:
LISTA DE FIGURASFigura 1 A - Freqü
- Page 12 and 13:
sonda A_14_P131252 que mapeia o gen
- Page 14 and 15:
esultante da análise do SAM (Tushe
- Page 16 and 17:
Figura 33 Agrupamento hierárquico
- Page 18 and 19:
LISTA DE TABELASQuadro 1Relação d
- Page 20 and 21:
LISTA DE SIGLAS E ABREVIATURASANG A
- Page 22 and 23:
SUMÁRIO1 Introdução ............
- Page 24 and 25:
Cirilo, PDRINTRODUÇÃO11. Introdu
- Page 26 and 27:
Cirilo, PDRINTRODUÇÃO3dados em li
- Page 28 and 29:
Cirilo, PDRINTRODUÇÃO5infertilida
- Page 30 and 31:
Cirilo, PDRINTRODUÇÃO7foram despe
- Page 32 and 33:
Cirilo, PDRINTRODUÇÃO9(10q24.33),
- Page 34 and 35:
Cirilo, PDRINTRODUÇÃO11somente fo
- Page 36 and 37:
Cirilo, PDRINTRODUÇÃO13Segundo a
- Page 38 and 39:
Cirilo, PDRINTRODUÇÃO15(Sargent e
- Page 40 and 41:
Cirilo, PDRINTRODUÇÃO171 geralmen
- Page 42 and 43:
Cirilo, PDRINTRODUÇÃO19transcrita
- Page 44 and 45:
Cirilo, PDRINTRODUÇÃO21amostras.
- Page 46 and 47:
Cirilo, PDRINTRODUÇÃO23evento que
- Page 48 and 49:
Cirilo, PDRINTRODUÇÃO25também os
- Page 50 and 51:
Cirilo, PDRINTRODUÇÃO27tratamento
- Page 52 and 53:
Cirilo, PDRINTRODUÇÃO29Hodge et a
- Page 54 and 55:
Cirilo, PDRMATERIAL E MÉTODOS313.
- Page 56 and 57:
Cirilo, PDRMATERIAL E MÉTODOS33Tam
- Page 58 and 59:
Cirilo, PDRMATERIAL E MÉTODOS35for
- Page 60 and 61:
Cirilo, PDRMATERIAL E MÉTODOS370,1
- Page 62 and 63:
Cirilo, PDRMATERIAL E MÉTODOS39alt
- Page 64 and 65:
Cirilo, PDRMATERIAL E MÉTODOS413)
- Page 66 and 67:
Cirilo, PDRRESULTADOS43Tabela 1. Da
- Page 68 and 69:
Cirilo, PDRRESULTADOS45ABFigura 1.
- Page 70 and 71:
Cirilo, PDRRESULTADOS47Este estudo
- Page 72 and 73:
Cirilo, PDRRESULTADOS494.2.1 Caract
- Page 74 and 75:
Cirilo, PDRRESULTADOS51Entre as 45
- Page 76 and 77:
Cirilo, PDRRESULTADOS53(10%)Cromoss
- Page 78 and 79:
Cirilo, PDRRESULTADOS55Cromossomo 1
- Page 80 and 81:
Cirilo, PDRRESULTADOS574.2.2 Tumore
- Page 82 and 83:
Cirilo, PDRRESULTADOS59Tabela 4. De
- Page 84 and 85:
Cirilo, PDRRESULTADOS61629T 629T_A,
- Page 86 and 87:
Cirilo, PDRRESULTADOS63279,263-1,48
- Page 88 and 89:
Cirilo, PDRRESULTADOS65ABFigura 7.
- Page 90 and 91:
Cirilo, PDRRESULTADOS67ABFigura 8 -
- Page 92 and 93:
ABCirilo, PDRRESULTADOS69Figura 10.
- Page 94 and 95:
Cirilo, PDRRESULTADOS71Figura 11. A
- Page 96 and 97:
Cirilo, PDRRESULTADOS73Grupo 1tumor
- Page 98 and 99:
Cirilo, PDRRESULTADOS75Figura 14. A
- Page 100 and 101:
Cirilo, PDRRESULTADOS77631T_C 99,55
- Page 102 and 103:
Cirilo, PDRRESULTADOS794.3 Análise
- Page 104 and 105:
Cirilo, PDRRESULTADOS81Tabela 7. Re
- Page 106 and 107:
ABCirilo, PDRRESULTADOS83Figura 16.
- Page 108 and 109:
Cirilo, PDRRESULTADOS85Figura 17. V
- Page 110 and 111:
Cirilo, PDRRESULTADOS87Figura 19. R
- Page 112 and 113:
Cirilo, PDRRESULTADOS894.3.1 Análi
- Page 114 and 115:
Cirilo, PDRRESULTADOS91Figura 22. A
- Page 116 and 117:
Cirilo, PDRRESULTADOS93Entre os cas
- Page 118 and 119:
Cirilo, PDRRESULTADOS95Figura 23. A
- Page 120 and 121:
Cirilo, PDRRESULTADOS97Tabela 8. Ge
- Page 122 and 123:
Cirilo, PDRRESULTADOS99HAPLN1 HAPLN
- Page 124 and 125:
Cirilo, PDRRESULTADOS101beta 4MYO10
- Page 126 and 127:
Cirilo, PDRRESULTADOS103DIO1 DIO1 d
- Page 128 and 129:
Cirilo, PDRRESULTADOS105inhibits CD
- Page 130 and 131:
Cirilo, PDRRESULTADOS107CENPK CENPK
- Page 132 and 133:
Cirilo, PDRRESULTADOS109pareamento
- Page 134 and 135:
Cirilo, PDRRESULTADOS111JUB, ↓MAG
- Page 136 and 137:
Cirilo, PDRRESULTADOS113Figura 25.
- Page 138 and 139:
Cirilo, PDRRESULTADOS115Figura 27.
- Page 140 and 141:
Cirilo, PDRRESULTADOS117Figura 29.
- Page 142 and 143:
Cirilo, PDRRESULTADOS1194.5.1 CGH a
- Page 144 and 145:
Cirilo, PDRRESULTADOS121Figura 32.
- Page 146 and 147:
Cirilo, PDRRESULTADOS123Tabela 10.
- Page 148 and 149:
Cirilo, PDRRESULTADOS125
- Page 150 and 151:
Cirilo, PDRRESULTADOS1274.5.3.1 Pre
- Page 152 and 153:
Cirilo, PDRRESULTADOS129PKP3 - -PRE
- Page 154 and 155:
Cirilo, PDRRESULTADOS131Tabela 12.
- Page 156 and 157:
Cirilo, PDRRESULTADOS133Perda (1) N
- Page 158 and 159:
ABCirilo, PDRRESULTADOS135Figura 33
- Page 160 and 161:
Cirilo, PDRRESULTADOS1374.5.3.4 Fre
- Page 162 and 163:
Cirilo, PDRRESULTADOS139Tabela 13.
- Page 164 and 165:
Cirilo, PDRRESULTADOS1414.5.3.6 An
- Page 166 and 167:
Cirilo, PDRRESULTADOS143Tabela 15.
- Page 168 and 169:
Cirilo, PDRRESULTADOS145ativação
- Page 170 and 171:
ACirilo, PDRRESULTADOS147BFigura 36
- Page 172 and 173:
Cirilo, PDRRESULTADOS149Figura 38.
- Page 174 and 175:
Cirilo, PDRDISCUSSÃO1515. Discuss
- Page 177 and 178:
Cirilo, PDRDISCUSSÃO154informaçõ
- Page 179 and 180:
Cirilo, PDRDISCUSSÃO156descritos g
- Page 181 and 182:
Cirilo, PDRDISCUSSÃO158uma proteí
- Page 183 and 184:
Cirilo, PDRDISCUSSÃO160celulares e
- Page 185 and 186:
Cirilo, PDRDISCUSSÃO162apresentado
- Page 187 and 188:
Cirilo, PDRDISCUSSÃO164q14). Porta
- Page 189 and 190: Cirilo, PDRDISCUSSÃO166Desde 1991,
- Page 191 and 192: Cirilo, PDRDISCUSSÃO168núcleo das
- Page 193 and 194: Cirilo, PDRDISCUSSÃO170sobre LHFPL
- Page 195 and 196: Cirilo, PDRDISCUSSÃO172outras cate
- Page 197 and 198: Cirilo, PDRDISCUSSÃO174Entre as ou
- Page 199 and 200: Cirilo, PDRDISCUSSÃO176regiões de
- Page 201 and 202: Cirilo, PDRDISCUSSÃO178da RNA Pol
- Page 203 and 204: Cirilo, PDRDISCUSSÃO180proliferati
- Page 205 and 206: Cirilo, PDRDISCUSSÃO182Entre os 20
- Page 207 and 208: Cirilo, PDRDISCUSSÃO184propôs um
- Page 209 and 210: Cirilo, PDRDISCUSSÃO186analisados
- Page 211 and 212: Cirilo, PDRDISCUSSÃO188observados
- Page 213 and 214: Cirilo, PDRDISCUSSÃO190moduladores
- Page 215 and 216: Cirilo, PDRDISCUSSÃO192genômica/d
- Page 217 and 218: Cirilo, PDRDISCUSSÃO194identificar
- Page 219 and 220: Cirilo, PDRDISCUSSÃO196e também d
- Page 221 and 222: Cirilo, PDRDISCUSSÃO198O gene COL3
- Page 223 and 224: Cirilo, PDRDISCUSSÃO200resistênci
- Page 225 and 226: Cirilo, PDRDISCUSSÃO202bioquímica
- Page 227 and 228: Cirilo, PDRDISCUSSÃO204carcinoma c
- Page 229 and 230: Cirilo, PDRCONCLUSÕES DISCUSSÃO20
- Page 231 and 232: Cirilo, PDRREFERÊNCIAS2087. Refer
- Page 233 and 234: Cirilo, PDRREFERÊNCIAS210Brazelle
- Page 235 and 236: Cirilo, PDRREFERÊNCIAS212Churikov
- Page 237 and 238: Cirilo, PDRREFERÊNCIAS214Gannon BR
- Page 239: Cirilo, PDRREFERÊNCIAS216Holthause
- Page 243 and 244: Cirilo, PDRREFERÊNCIAS220Lloret M,
- Page 245 and 246: Cirilo, PDRREFERÊNCIAS222Mitra R,
- Page 247 and 248: Cirilo, PDRREFERÊNCIAS224Ozisik YY
- Page 249 and 250: Cirilo, PDRREFERÊNCIAS226Redon R,
- Page 251 and 252: Cirilo, PDRREFERÊNCIAS228Solyom S,
- Page 253 and 254: Cirilo, PDRREFERÊNCIAS230Ueki K, R
- Page 255 and 256: Cirilo, PDRREFERÊNCIAS232and poly(
- Page 257 and 258: Skubitz KM e Skubitz APJ Lab Clin M
- Page 259 and 260: Dimitrova IK et al. Fertil Steril,9
- Page 261 and 262: 317T_B317T_C13 614T 44 LU prolifera
- Page 263 and 264: 46 867T 46 LUM outros B 14 33,5 17
- Page 265 and 266: 1015T 6q13-q14.1 75,806,978-76,314,
- Page 267 and 268: MRPS31, SLC25A15, SUGT1L1 320d-1630
- Page 269 and 270: 8q22.3-q23.1 105,831,966 107,742,33
- Page 271 and 272: Anexo 5. Genes identificados na an
- Page 273 and 274: + + CCDC8 0 51 37 14+ - CALM3 51 0
- Page 275 and 276: ABSTRACTBackground: Uterine leiomyo
- Page 277 and 278: Thus, these findings prompt us to i
- Page 279 and 280: Technologies, Santa Clara, CA). Sta
- Page 281 and 282: mapped at 1p36.13, 1q41, 2q32.1, 2q
- Page 283 and 284: genetic disorder showed the higher
- Page 285 and 286: The modulators were mainly associat
- Page 287 and 288: egulation of cell cycle. Chegini an
- Page 289 and 290: REFERENCES[1] Baird DD, Dunson DB (
- Page 291 and 292:
[37] Luo X, Ding L, Xu J et al. (20
- Page 293 and 294:
AArray CGHExpression arrayBtumoral
- Page 295 and 296:
ABDiseases and Disorders P value Mo
- Page 298 and 299:
Tabel 2. Genes identified on module
- Page 300 and 301:
Table S1. Clinical parameters and h
- Page 302 and 303:
32 954T 45 M secretory W 12 33,7 18
- Page 304 and 305:
16 28184420-30915100 2730680 p11.2
- Page 306 and 307:
MYPN hsa-miR-214 -NFKBIL2 - -PKP3 -
- Page 308:
Table S5. Ingenuity Pathways Analys